Ablynx teams up with AIM for the design and implementation of its commercial supply chain for caplacizumab.
The European Commission has granted marketing authorization for Cablivi™ (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.
In preparation of the launch of caplacizumab, Ablynx decided to partner with AIM to design its commercial supply chain for Europe, US and Canada. Given the rare and acute nature of the disease, a highly-specialized supply chain design needed to be developed. The design by AIM did not only cover the logistical aspects but also...
AIM WAS PRESENT AT THIS YEAR’S BIOEUROPE (2018) IN COPENHAGEN
AIM decided to be present and to have a booth at BioEurope in Copenhagen. The booth demonstrated AIM’s capability and extensive experience to assist start-up Life Science companies to create their EU supply chain. Some valuable relationships were created and “old” friendships were renewed. It was appreciated and recognized that having a robust and efficient supply chain is imperative for a successful launch in Europe.
AIM LAUNCHES NEW WEBSITE
AIM decided to launch a new state of the art website in order to better reflect the company’s current capabilities and expertise. The new site will zoom in on AIM’s core activities like supporting life science start-ups creating their European supply chain, providing supply chain consultancy, interim professional services and supply chain maintenance services. The website will go live in November.